G1 Therapeutics Phase 3 Trial Update: Market Response
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
- Latest
- Trending
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Flame Acquisition shareholders have approved the business combination with Sable Offshore, paving the way for new opportunities and growth in ...
Medical technology company TransMedics Group, Inc. is set to release its Q4 and full year 2023 financial results, highlighting its ...
Arista Networks reports a revenue increase of 33.8% in 2023, reaching $5.86 billion. The company's impressive financial results and innovation ...
CareerViewXR has donated virtual reality headsets to all middle and high schools in North Dakota, allowing students to explore different ...
The opening of Red Mile Gaming's sportsbook in Kentucky allowed residents to legally bet on the Super Bowl for the ...
Safehold Inc. reports positive financial results for Q4 and FY2023, with increased revenue, adjusted net income, and an upgraded credit ...
Quik Exchange is revolutionizing the NFT marketplace with innovative features and community engagement. With thousands of listings and transactions in ...
A company has launched various objects into orbit for advertising purposes, showcasing its investment in research and development. This innovative ...
Shares of banks and other financial institutions have risen as investors await key inflation data. The possibility of rate cuts ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.